GO:1901594 response to capsazepine: TRPV1 Antagonism Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901594 (response to capsazepine) describes any cellular or organismal process that changes as a result of a capsazepine stimulus, as defined by QuickGO.
• Capsazepine is a synthetic capsaicin analogue best known as a TRPV1 antagonist, so most documented responses involve TRPV1-dependent sensory and immune signaling [1,2,8].
• Capsazepine-responsive processes include corneal pain signaling in dry eye disease, airway cholinergic responses, L-DOPA-induced dyskinesia, itch, macrophage polarization, renal sympathetic outflow, and cutaneous vasodilation [1,2,3,4,5,6,7].
• Key molecular players in response to capsazepine include TRPV1, histamine H4 receptor, MAPK/NF-kB pathway components, and neurotransmitter release machinery [2,4,5].
• Studying GO:1901594 requires integrated approaches such as calcium imaging, electrophysiology, cytokine profiling, and CRISPR-based gene editing of TRPV1-pathway genes [1,3,5].
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening to dissect response to capsazepine mechanisms.
Description
GO:1901594, response to capsazepine, is a Gene Ontology biological process term that captures any change in state or activity of a cell or organism as a result of a capsazepine stimulus. Capsazepine is a synthetic capsaicin analogue widely used experimentally as a TRPV1 antagonist, and its application triggers measurable changes in sensory neuron activity, immune cell behavior, and autonomic responses [1,2,8]. Because capsazepine is a pharmacological tool rather than an endogenous ligand, the term is most relevant to researchers probing TRPV1-dependent and TRPV1-independent signaling in pain, inflammation, and neuro-immune crosstalk [1,3,5]. The QuickGO definition is deliberately broad, encompassing movement, secretion, enzyme production, and gene expression changes, which makes GO:1901594 a useful annotation target for studies that perturb TRPV1 pathways pharmacologically [1,2,4]. Understanding this term helps researchers connect pharmacological observations to specific molecular mechanisms and disease models, from corneal pain in dry eye disease to L-DOPA-induced dyskinesia in Parkinsonian mice [1,3].
response to capsazepine At A Glance
| GO ID | GO:1901594 |
|---|---|
| GO term | response to capsazepine |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a capsazepine stimulus. |
| Major function | Captures cellular and organismal responses to the TRPV1 antagonist capsazepine, including sensory, immune, and autonomic changes. |
| Representative stimuli | Capsazepine, a synthetic capsaicin analogue and TRPV1 antagonist [1,2,8]. |
| Example biological contexts | Corneal pain in dry eye disease, airway cholinergic responses, L-DOPA-induced dyskinesia, itch, macrophage polarization, renal sympathetic response, cutaneous vasodilation [1,2,3,4,5,6,7]. |
| Key molecular players | TRPV1, histamine H4 receptor, MAPK/NF-kB pathway components [2,4,5]. |
What Is GO:1901594?
In plain terms, GO:1901594 describes everything that happens inside a cell or organism after it encounters capsazepine. According to QuickGO, it is any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a capsazepine stimulus. This includes rapid events such as ion channel modulation and neurotransmitter release, as well as slower transcriptional and immune responses [1,2,5].
Why Is response to capsazepine Important in Cell Biology?
Response to capsazepine is important because capsazepine is one of the most widely used pharmacological tools to interrogate TRPV1 function in vivo and in vitro, and the biological processes it triggers span pain, inflammation, immunity, and autonomic control [1,2,5,8]. Annotating and studying GO:1901594 allows researchers to systematically link capsazepine exposure to downstream cellular outcomes, which is essential for interpreting experiments that use capsazepine as a TRPV1 antagonist or as a probe for TRPV1-independent effects [1,3,4].
• Capsazepine reduces corneal pain syndrome in severe dry eye disease, linking GO:1901594 to ocular pain research.
• Capsazepine-sensitive receptors mediate inhibition of tracheal responses to endogenously released acetylcholine, connecting the term to airway physiology.
• Capsazepine combined with 4'-fluorocannabidiol restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice via anti-inflammatory and anti-glutamatergic mechanisms.
• Capsazepine is used to probe TRPV1 involvement in cadaverine-induced itch through histamine H4 receptor and TRPV1 pathways.
• Capsazepine modulates TRPV1-MAPK/NF-kB signaling in alcohol-induced macrophage M2b polarization in colitis.
• Capsazepine influences biphasic renal sympathetic responses to hemorrhagic hypotension in mice.
• Capsazepine affects sensory nerve contributions to cutaneous vasodilator responses.
• Capsazepine modulates innate immune responses in Plasmodium berghei ANKA-infected mice.
• The term supports cross-species and multi-system research, from sensory neurons to immune cells and autonomic circuits [1,5,6].
• GO:1901594 provides a standardized annotation for pharmacological studies using capsazepine, improving data integration and reproducibility [1,2,8].
What Happens During response to capsazepine?
Capsazepine recognition and TRPV1 antagonism
In simple terms: Capsazepine binds to TRPV1 and blocks its activity, which is the first step in the response.
Capsazepine is a synthetic capsaicin analogue that acts as a TRPV1 antagonist, and its application is used experimentally to block TRPV1-mediated signaling [1,2,8]. In the context of GO:1901594, the initial event is the interaction of capsazepine with TRPV1 or other capsazepine-sensitive targets, leading to altered ion flux and downstream signaling [2,8]. This recognition step is critical because it determines whether subsequent cellular changes are TRPV1-dependent or involve additional pathways [1,4].
Sensory neuron modulation and pain signaling
In simple terms: Capsazepine changes how sensory neurons send pain signals.
Capsazepine decreases corneal pain syndrome in severe dry eye disease, indicating that response to capsazepine includes modulation of corneal sensory neuron activity. In airway studies, R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors, showing that capsazepine-responsive processes extend to cholinergic control in the airways. These findings support the view that GO:1901594 encompasses sensory and autonomic modulation relevant to pain and airway physiology [1,2].
Neuro-immune and inflammatory signaling
In simple terms: Capsazepine can change immune cell behavior and inflammation.
Capsazepine combined with 4'-fluorocannabidiol restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice through anti-inflammatory and anti-glutamatergic mechanisms, linking response to capsazepine to neuroinflammation. Alcohol induces macrophage M2b polarization in colitis by modulating TRPV1-MAPK/NF-kB pathways, and capsazepine is used to interrogate this axis. Additionally, TRPV1 antagonism by capsazepine modulates innate immune responses in mice infected with Plasmodium berghei ANKA, demonstrating that GO:1901594 includes immune response changes.
Itch and histamine H4 receptor crosstalk
In simple terms: Capsazepine affects itch signaling involving histamine receptors.
Histamine H4 receptor and TRPV1 mediate itch induced by cadaverine, a microbiome metabolite, and capsazepine is used to probe TRPV1 involvement in this response. This places GO:1901594 within the broader context of pruriceptive signaling and microbiome-host interactions, where capsazepine-sensitive pathways contribute to sensory outcomes.
Autonomic and vascular responses
In simple terms: Capsazepine can alter sympathetic nerve activity and blood vessel responses.
Biphasic renal sympathetic response to hemorrhagic hypotension in mice involves capsazepine-sensitive mechanisms, indicating that response to capsazepine includes autonomic regulation. Sensory nerves contribute to cutaneous vasodilator response to cathodal stimulation in healthy rats, and capsazepine is used to assess this contribution. Together, these studies show that GO:1901594 spans autonomic and vascular physiology [6,7].
Key Genes Involved in GO:1901594 response to capsazepine
The following genes and proteins are experimentally implicated in response to capsazepine, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRPV1 | Primary capsazepine target; ion channel mediating sensory and inflammatory signaling | Central to capsazepine studies in pain, itch, colitis, and immune responses [1,2,4,5,8] |
| HRH4 | Histamine H4 receptor; mediates itch signaling with TRPV1 | Implicated in cadaverine-induced itch and capsazepine-sensitive pathways |
| MAPK1 | MAPK pathway component downstream of TRPV1 | Involved in alcohol-induced macrophage polarization via TRPV1-MAPK/NF-kB |
| NFKB1 | NF-kB pathway component downstream of TRPV1 | Modulates inflammatory responses in colitis and immune cells |
| TNF | Pro-inflammatory cytokine | Potential downstream effector of capsazepine-modulated inflammation [3,5] |
| IL6 | Pro-inflammatory cytokine | Associated with inflammatory responses in capsazepine studies [3,5] |
| IL10 | Anti-inflammatory cytokine | Linked to macrophage polarization changes in colitis |
| CHAT | Choline acetyltransferase; acetylcholine synthesis | Relevant to tracheal responses involving capsazepine-sensitive receptors |
| ACHE | Acetylcholinesterase; acetylcholine breakdown | Related to cholinergic signaling in airway studies |
| SCN9A | Voltage-gated sodium channel in sensory neurons | Potential contributor to sensory neuron excitability in capsazepine studies |
| P2RX3 | ATP-gated ion channel in sensory neurons | Sensory neuron marker relevant to pain and itch pathways [1,4] |
| TRPA1 | Sensory ion channel often co-expressed with TRPV1 | Potential crosstalk in capsazepine-sensitive responses |
| GAD1 | Glutamate decarboxylase; GABA synthesis | Relevant to anti-glutamatergic mechanisms in dyskinesia |
| GRIN1 | NMDA receptor subunit; glutamatergic signaling | Linked to anti-glutamatergic effects in L-DOPA-induced dyskinesia |
| TH | Tyrosine hydroxylase; dopamine synthesis | Relevant to hemiparkinsonian mouse models |
| DRD1 | Dopamine receptor D1 | Associated with dyskinesia and dopaminergic signaling |
| DRD2 | Dopamine receptor D2 | Associated with dyskinesia and dopaminergic signaling |
| NOS1 | Neuronal nitric oxide synthase | Potential mediator of vascular and autonomic responses [6,7] |
How Is response to capsazepine Regulated?
Response to capsazepine is regulated at multiple levels. At the receptor level, TRPV1 antagonism by capsazepine directly modulates channel activity, which can be influenced by phosphorylation and desensitization [1,2,8]. Downstream, MAPK and NF-kB pathways mediate transcriptional changes in immune cells, as shown in alcohol-induced macrophage polarization. In neuroinflammatory contexts, anti-inflammatory and anti-glutamatergic mechanisms contribute to capsazepine effects in dyskinesia models. Additionally, histamine H4 receptor signaling interacts with TRPV1 in itch pathways, indicating receptor crosstalk. Autonomic regulation, including renal sympathetic responses, further shapes organism-level outcomes.
response to capsazepine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRPV1 | Dry eye disease, corneal pain | TRPV1 knockout mice or corneal sensory neuron cultures |
| TRPV1 | L-DOPA-induced dyskinesia in Parkinson's disease | Hemiparkinsonian mice with capsazepine treatment |
| TRPV1 | Colitis and macrophage polarization | Macrophage-specific TRPV1 knockout in colitis models |
| HRH4 | Itch and pruriceptive signaling | HRH4 knockout mice or sensory neuron cultures |
| TRPV1 | Plasmodium berghei ANKA infection | TRPV1 knockout mice infected with P. berghei |
Dry eye disease and corneal pain
Capsazepine decreases corneal pain syndrome in severe dry eye disease, suggesting that response to capsazepine is directly relevant to ocular pain management. This links GO:1901594 to sensory neuron dysfunction in dry eye and supports TRPV1 as a therapeutic target.
Parkinson's disease and L-DOPA-induced dyskinesia
In hemiparkinsonian mice, 4'-fluorocannabidiol combined with capsazepine restrains L-DOPA-induced dyskinesia through anti-inflammatory and anti-glutamatergic mechanisms. This implicates response to capsazepine in modulating neuroinflammation and glutamatergic signaling in Parkinson's disease models.
Inflammatory bowel disease and colitis
Alcohol induces macrophage M2b polarization in colitis by modulating TRPV1-MAPK/NF-kB pathways, and capsazepine is used to dissect this response. Thus, GO:1901594 is relevant to intestinal inflammation and macrophage biology.
Infectious disease and innate immunity
TRPV1 antagonism by capsazepine modulates innate immune responses in mice infected with Plasmodium berghei ANKA, indicating a role for response to capsazepine in host-pathogen interactions. This expands the disease relevance of GO:1901594 to malaria and innate immunity.
From response to capsazepine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TRPV1 mediate capsazepine-induced pain relief in dry eye? | TRPV1 knockout mouse model |
| Is TRPV1 required for capsazepine effects on L-DOPA-induced dyskinesia? | TRPV1 knockout hemiparkinsonian mice |
| Does histamine H4 receptor interact with TRPV1 in itch? | HRH4 point-mutation or knockout mice |
| How does TRPV1 modulate macrophage polarization in colitis? | Macrophage-specific TRPV1 knockout or overexpression |
| What is the role of TRPV1 in renal sympathetic responses? | TRPV1 knockout mice with hemorrhagic hypotension |
| Does TRPV1 contribute to cutaneous vasodilation? | TRPV1 knockout rats or sensory nerve ablation models |
How to Study the response to capsazepine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium flux | TRPV1 activation in sensory neurons [1,2] |
| Patch-clamp electrophysiology | Ion channel currents | Capsazepine effects on TRPV1 |
| Behavioral pain assays | Nociceptive responses | Corneal pain in dry eye models |
| Itch behavior tests | Scratching behavior | Cadaverine-induced itch |
| Flow cytometry | Immune cell phenotypes | Macrophage polarization in colitis |
| Cytokine ELISA | Protein levels of TNF, IL-6, IL-10 | Inflammatory responses to capsazepine [3,5] |
| RNA-seq | Transcriptome-wide gene expression | Pathway analysis after capsazepine treatment |
| Western blot | Protein phosphorylation and expression | MAPK/NF-kB signaling |
Calcium imaging and electrophysiology
Calcium imaging and patch-clamp electrophysiology are used to measure TRPV1 channel activity and sensory neuron responses to capsazepine [1,2]. These methods directly assess the immediate cellular changes that define GO:1901594 [1,2].
Behavioral and pain assays
Corneal pain assays in dry eye models and itch behavior tests are used to quantify organism-level responses to capsazepine [1,4]. These approaches link molecular events to behavioral outcomes relevant to GO:1901594 [1,4].
Immune cell profiling and cytokine analysis
Flow cytometry, cytokine ELISAs, and macrophage polarization assays are used to measure immune changes following capsazepine treatment [5,8]. These methods capture the inflammatory and immune dimensions of response to capsazepine [5,8].
Transcriptomics and pathway analysis
RNA-seq and pathway enrichment analysis can identify gene expression changes downstream of capsazepine exposure, including MAPK/NF-kB targets. Such approaches help define the transcriptional scope of GO:1901594.
How CRISPR Can Be Used to Study GO:1901594 response to capsazepine
Knockout
CRISPR knockout of TRPV1 or HRH4 can be used to test whether capsazepine responses are receptor-dependent [1,4]. Knockout cell models enable loss-of-function studies in sensory neurons, macrophages, and other relevant cell types [1,5].
Point Mutation
Point mutations in TRPV1 can be introduced to dissect capsazepine binding and channel gating. Such models help distinguish TRPV1-dependent from TRPV1-independent effects of capsazepine [2,8].
Knock-in
Knock-in of tagged TRPV1 or reporter alleles allows visualization and tracking of capsazepine-responsive cells in vivo [1,3]. This approach supports precise mapping of response to capsazepine in complex tissues [1,3].
Overexpression
Overexpression of TRPV1 or downstream signaling components can enhance capsazepine responses and facilitate biochemical assays [5,8]. Overexpression models are useful for studying gain-of-function effects in immune and sensory cells [5,8].
How EDITGENE Supports response to capsazepine Research
Researchers studying response to capsazepine-related genes often need to determine whether a candidate gene is causally involved in TRPV1-dependent or TRPV1-independent signaling. EDITGENE provides validated CRISPR models to test these hypotheses with precision.
Contact EDITGENE today to design your custom CRISPR model for response to capsazepine research.
Frequently Asked Questions About response to capsazepine
What is GO:1901594?
GO:1901594 is the Gene Ontology biological process term for response to capsazepine, defined as any process that results in a change in state or activity of a cell or organism as a result of a capsazepine stimulus.
What is response to capsazepine?
Response to capsazepine refers to the cellular and organismal changes triggered by capsazepine, a synthetic capsaicin analogue and TRPV1 antagonist [1,2,8].
What genes are involved in response to capsazepine?
Key genes include TRPV1, HRH4, MAPK1, NFKB1, and inflammatory cytokines such as TNF and IL6 [1,2,4,5].
How is capsazepine used in research?
Capsazepine is used experimentally as a TRPV1 antagonist to study pain, itch, inflammation, and autonomic responses [1,2,4,5,6,7,8].
What diseases are linked to response to capsazepine?
Dry eye disease, Parkinson's disease dyskinesia, colitis, itch, and malaria infection have been linked to capsazepine-responsive pathways [1,3,4,5,8].
What methods study response to capsazepine?
Calcium imaging, electrophysiology, behavioral assays, flow cytometry, cytokine ELISAs, and RNA-seq are commonly used [1,2,4,5].
Can CRISPR be used to study response to capsazepine?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can dissect gene function in capsazepine responses [1,2,3,5,8].
What is the role of TRPV1 in response to capsazepine?
TRPV1 is the primary target of capsazepine, and its antagonism mediates many downstream effects [1,2,8].
How does capsazepine affect immune cells?
Capsazepine modulates macrophage polarization and innate immune responses via TRPV1-MAPK/NF-kB pathways [5,8].
Where can I get CRISPR models for response to capsazepine research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression, and library screening services for capsazepine-related genes.
Conclusion
GO:1901594 (response to capsazepine) is a biologically meaningful Gene Ontology term that captures the diverse cellular and organismal changes triggered by capsazepine, a widely used TRPV1 antagonist. From corneal pain and itch to neuroinflammation and autonomic control, the processes annotated under this term are supported by a robust body of published literature [1,2,3,4,5,6,7,8]. Researchers can leverage CRISPR-based models and multi-omics methods to dissect the molecular players and pathways underlying response to capsazepine, advancing both basic sensory biology and therapeutic development.
References
- 1. Fakih D et al.. 2021. Capsazepine decreases corneal pain syndrome in severe dry eye disease.. J Neuroinflammation 18(1):111 PMID: 33975636
- 2. Nieri P et al.. 2003. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.. Eur J Pharmacol 459(1):75-81 PMID: 12505536
- 3. Dos Santos Pereira M et al.. 2024. 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.. Neuropharmacology 251:109926 PMID: 38554815
- 4. Sun SY et al.. 2024. Histamine H4 receptor and TRPV1 mediate itch induced by cadaverine, a metabolite of the microbiome.. Mol Pain 20:17448069241272149 PMID: 39079948
- 5. Zhang Z et al.. 2024. Alcohol inducing macrophage M2b polarization in colitis by modulating the TRPV1-MAPK/NF-κB pathways.. Phytomedicine 130:155580 PMID: 38810558
- 6. Zhang T et al.. 2017. Biphasic Renal Sympathetic Response to Hemorrhagic Hypotension in Mice.. Shock 48(5):576-582 PMID: 28459715
- 7. Gohin S et al.. 2015. Sensory nerves contribute to cutaneous vasodilator response to cathodal stimulation in healthy rats.. Microvasc Res 101:103-10 PMID: 26205659
- 8. Fernandes ES et al.. 2014. TRPV1 antagonism by capsazepine modulates innate immune response in mice infected with Plasmodium berghei ANKA.. Mediators Inflamm 2014:506450 PMID: 25242870
